Sign In
Buy DXCM
$82.66
-4.28 (-4.92%)
At Close: Aug 05, 2026
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
08:45am, Monday, 13'th May 2024
Moderna has a deep pipeline that should help it land brand-new approvals regularly. DexCom has a massive opportunity in the vast continuous glucose monitoring market.
DexCom: Attractive Discount After Strong Earnings Results
03:26am, Monday, 06'th May 2024
DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch
Shhh! 3 Secret IoT Stocks Flying Below Wall Street's Radar
10:00am, Friday, 03'rd May 2024
IoT's benefit lies in its capacity to enhance convenience, efficiency and safety across various domains. IoT enables real-time monitoring and data exchange by connecting everyday objects to the intern
Here is Why Growth Investors Should Buy DexCom (DXCM) Now
01:45pm, Tuesday, 30'th Apr 2024
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Tuesday, 30'th Apr 2024
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why DexCom (DXCM) is a Strong Growth Stock
10:46am, Monday, 29'th Apr 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
08:30am, Friday, 26'th Apr 2024
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom, Inc. (DXCM) Q1 2024 Earnings Call Transcript
07:36pm, Thursday, 25'th Apr 2024
DexCom, Inc. (NASDAQ:DXCM ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman,
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
07:01pm, Thursday, 25'th Apr 2024
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to
Dexcom Plummets After Raising Its Sales Guidance For The Year — But Not Enough
04:46pm, Thursday, 25'th Apr 2024
Dexcom stock plunged late Thursday after the company raised its sales outlook for the year, but not enough to satisfy investors.
Dexcom Reports First Quarter 2024 Financial Results
04:03pm, Thursday, 25'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #dexcom--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights:
Medtech Marvels: 3 Groundbreaking Medical Device Stocks to Watch in 2024
06:00am, Thursday, 25'th Apr 2024
The value of the “global medical device market” is expected to jump from over $500 billion last year to nearly $800 billion “by 2030.” According to the World Health Organization, “a medical
Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?
10:32am, Wednesday, 24'th Apr 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:22am, Monday, 22'nd Apr 2024
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week
08:30am, Friday, 19'th Apr 2024
Dexcom stock is in a buy zone ahead of earnings next week. Shares rallied after the company launched a prescription-free glucose monitoring device.
